EUCTR2005-004105-28-IE
进行中（未招募）
1 期
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- PDL BioPharma, Inc.
- 入组人数
- 300
- 状态
- 进行中（未招募）
- 最后更新
- 5年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- •1\) Previous participation in an IVSR\-UC visilizumab study.
- •2\) Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- •1\) Unable to understand the purpose and risks of the study, or unwilling or unable to provide signed and dated informed consent.
- •2\) For U.S. sites, unwilling or unable to provide authorization to use protected health information.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-004105-28-GRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-004105-28-NLPDL BioPharma, Inc300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SEUCTR2005-004105-28-DEPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SEUCTR2005-004105-28-FRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.EUCTR2005-004105-28-GBPDL BioPharma, Inc.300